Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today announced the launch of the first phase of its multimillion-dollar national marketing campaign. The campaign will highlight OPTAVIA's new offering in collaboration with LifeMD®, the GLP-1 Lifestyle Program, a holistic approach to medical weight loss specifically tailored to support the needs of those utilizing GLP-1 medications. This rob.

Medifast Continues Business Transformation, Launching National Marketing Campaign Promoting its Holistic Offering for Customers Utilizing and Considering Weight Loss Medications

Ares Commercial Real Estate

AGNC Investment

Apollo Commercial Real Estate Finance

Chevron

FS KKR Capital Corp

Intel

Johnson & Johnson

Orchid Island Capital

Oxford Lane Capital

PIMCO Dynamic Income Fund

Ready Capital Corp

V.F.

Prior to April 30, 2024, my Readers mentioned 31 equities in their comments on my articles. Some bad-news investments (Rogues) mixed with (mostly) Favorites. Thus, they remarked about the ReFa/Ro. Ten analyst-target-estimated top net gain ReFa/Ro: ORC, JNJ, CVX, FTN.CA, OXLC, ACRE, MED, RC, INTC, and VFC averaged 22.94% net gains from reader data collected 5/15/23. Ten analyst-target-augured April top price upside reader faves & rogues (ReFa/Ro) were: ORI, O, KVUE, PFE, WES, CVX, JNJ, RC, INTC & VFC boasting a 16.43% average target price upside estimate.

Readers Identify 23 Ideal April Dividend Buys

LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm

Arbor Realty Trust

B. Riley Financial

SunPower

Comstock Resources

Guess?

GameStop

Kohl's

Medical Properties Trust

Trupanion

Vital Energy Inc

Meme-stock maven Roaring Kitty surfaced on social media again to hype GameStop shares. But there are better targets beyond the S&P 500.

10 Stocks 'Roaring Kitty' Should Target Next Instead Of GameStop

Apartment Income REIT Corp

Costamare

Cricut

Garrett Motion

Steelcase

Connexa Sports Technologies In

As the S&P 500 races toward new highs, some investors see small-cap value stocks as the best bet for long-term growth amid growing concerns about index-based stock concentration. As mega-caps like Nvidia (NASDAQ: NVDA ) disproportionately drive the S&P 500's performance, the index becomes more vulnerable to fluctuations—a few missteps could significantly impact your entire portfolio.

Pocket-Sized Powerhouses: 7 Small-Cap Value Stocks Ready to Roar

Medifast's (MED) first-quarter results reflect challenges related to a decline in active earning OPTAVIA Coaches, lower coach productivity and soft sales volume.

Medifast (MED) Q1 Earnings Miss Estimates, Revenues Fall Y/Y

Medifast (NYSE: MED ) stock is falling on Tuesday after the weight loss company released its earnings report for the first quarter of 2024. The bad news for MED stock comes from its adjusted earnings per share of 66 cents.

Why Is Medifast (MED) Stock Down 20% Today?

Medifast, Inc. (NYSE:MED ) Q1 2024 Earnings Call Transcript April 29, 2024 4:30 PM ET Company Participants Steven Zenker - VP, IR Dan Chard - Chairman & CEO James Maloney - CFO Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson Operator Greetings.

Medifast, Inc. (MED) Q1 2024 Earnings Call Transcript

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2024. First Quarter 2024 Revenue of $174.7 million, with revenue per active earning coach of $4,623 Independent active earning OPTAVIA Coaches of 37,800 Net income of $8.3 million (non-GAAP adjusted net income of $7.2 million) Earnings per diluted share ("EPS") of $0.76 (non-GAAP ad.

Medifast Announces First Quarter 2024 Financial Results

Autohome

Bancolombia

DHT Holdings

Eagle Bancorp

Euronav

Golub Capital BDC

HSBC Holdings

Hercules Capital

Blue Owl Capital Corp

Petroleo Brasileiro

Provident Financial Services

Sandy Spring Bancorp

Sociedad Quimica Y Minera De Chile

Trimble

Vale S.A.

Large Cap Value is a value ranking for large cap stocks that looks at the price of a stock relative to measurements of intrinsic firm value. The Ben Graham Formula strategy selects ultra-stable stocks based on criteria such as sales, earnings, and dividend payments. 54 out of 65 All-Star-Value Dividend stocks offer annual dividends that exceed their price per share.

65 Graham Value Stocks: 54 Fit To Buy For April

Medifast (MED) adapts to shifting consumer behavior to maintain its relevance. However, it is facing difficulties in attracting customers due to the rapidly changing economy and inflation.

Medifast's (MED) Transformation on Track Amid Macro Headwinds

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the first quarter ended March 31, 2024 on Monday, April 29, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. T.

Medifast to Announce Financial Results for the First Quarter Ended March 31, 2024

Apple

Agree Realty

Automatic Data Processing

Broadcom

Bristol-Myers

CVS Health

Dominion Energy

Dollar General

Digital Realty Trust

EOG Resources

Hormel Foods

Kinder Morgan

Lennox International

Mastercard

McCormick

Microsoft

NextEra Energy

NXP Semiconductors

Realty Income Corp

Bank OZK

Philip Morris

The stock market shrugged off rising interest rates and global unrest to produce strong gains during 2023.

DGI For The DIY: 2023 Dividend Portfolio Review

Granite Ridge Resources Inc

Dorian LPG

Rio Tinto plc Sponsored

Ternium

Large Cap Value ranking from YCharts identifies stocks with low prices relative to their assets and profits. Ben Graham Formula strategy selects stable stocks with strong earnings and dividends based on Graham's book "The Intelligent Investor". 57 out of 68 All-Star-Value Dividend stocks offer annual dividends exceeding their price per share.

68 Graham Value Stocks, 57 Fit To Buy In March

Medifast (MED) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Medifast (MED) Soars 5.9%: Is Further Upside Left in the Stock?

Bunge Global SA

Conagra Brands

Fidelity MSCI Consumer Staples ETF

Invesco S&P 500 Equal Weight Consumer Staples ETF

Molson Coors Brewing

USANA Health Sciences

Consumer Staples Select Sector SPDR Fund

The tobacco and household products industries show the best value scores in the sector.

FSTA: Consumer Staples Sector Dashboard For March

Medifast (MED) is foraying into medically supported weight management and sports nutrition segments. However, it continues to encounter difficulties in attracting customers.

Innovations Aid Medifast (MED), Lower Customer Attraction Ails

Albertsons Companies

One tool that bargain hunters can utilize to identify beaten up stocks to buy after significant declines is the relative strength index ( RSI ). The RSI signals when a stock's downward momentum may be exhausted, indicating that a correction could provide upside potential.

Hey, Bottom Fishers! 3 Beaten Up Stocks to Buy for Short-Term Gains

Medifast is experiencing a decline in stock price despite a strong business and consistent cash flow.

Medifast Is Getting Attractive

News for Medifast Stock (MED)